Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Accumulated Expenses (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Accumulated Expenses for 3 consecutive years, with $12.3 million as the latest value for Q4 2024.

  • On a quarterly basis, Accumulated Expenses fell 15.55% to $12.3 million in Q4 2024 year-over-year; TTM through Dec 2024 was $12.3 million, a 15.55% decrease, with the full-year FY2024 number at $12.3 million, down 15.55% from a year prior.
  • Accumulated Expenses was $12.3 million for Q4 2024 at Spruce Biosciences, up from $7.7 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $14.6 million in Q4 2023 to a low of $5.4 million in Q1 2022.
  • A 3-year average of $9.6 million and a median of $8.7 million in 2023 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: soared 60.97% in 2023, then crashed 33.37% in 2024.
  • Spruce Biosciences' Accumulated Expenses stood at $9.4 million in 2022, then surged by 55.34% to $14.6 million in 2023, then dropped by 15.55% to $12.3 million in 2024.
  • Per Business Quant, the three most recent readings for SPRB's Accumulated Expenses are $12.3 million (Q4 2024), $7.7 million (Q3 2024), and $7.9 million (Q2 2024).